Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | JAK2 | O60674 | 2/20 | 0.32 |
| ▸ | JAK1 | P23458 | 2/20 | 0.32 |
| ▸ | TYK2 | P29597 | 2/20 | 0.32 |
| ▸ | JAK3 | P52333 | 2/20 | 0.32 |
| ▸ | SSTR4 | P31391 | 2/20 | 0.32 |
| ▸ | CNR2 | P34972 | 5/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.31 |
| ▸ | NPR3 | P17342 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21856426 | 0.76 | FEN1 (0.36) | SSTR4 | |
| SCHEMBL21774661 | 0.74 | TRPV3 (0.36) | LMNAKMT2AJAK2JAK1TYK2 | |
| SCHEMBL21856446 | 0.71 | MTNR1A (0.35) | GPR119SSTR4CNR2 | |
| SCHEMBL31582472 | 0.71 | JAK2 (0.34) | LMNAKMT2AJAK2JAK1TYK2 | |
| SCHEMBL31071943 | 0.69 | CNR2 (0.38) | LMNAKMT2AJAK2JAK1TYK2 | |
| SCHEMBL25718368 | 0.69 | CYP11B2 (0.33) | — | |
| SCHEMBL31582967 | 0.69 | HTR3A (0.34) | LMNAKMT2AJAK2JAK1TYK2 | |
| SCHEMBL21856380 | 0.68 | TRPA1 (0.33) | GPR119SSTR4CNR2CNR1 | |
| SCHEMBL28566111 | 0.68 | CNR2 (0.33) | GPR119LMNAKMT2ASSTR4CNR2 | |
| SCHEMBL24191487 | 0.66 | CYP11B2 (0.32) | SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12528803-B2 | Inhibitors of αvβ6 integrin | MORPHIC THERAPEUTIC, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-3844162-B1 | INHIBITORS OF ALPHA V BETA6 INTEGRIN | MORPHIC THERAPEUTIC INC (US) | 2025-01-01 | — | — | EP | disclosed |
| US-20230242524-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242524-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-08-03 | — | — | US | disclosed |
| US-20230242524-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | MORPHIC THERAPEUTIC, INC. | 2023-08-03 | — | — | US | disclosed |
| EP-3844162-A1 | INHIBITORS OF av beta6 INTEGRIN | Morphic Therapeutic, Inc. (US) | 2021-07-07 | — | — | EP | disclosed |
| WO-2020081154-A1 | INHIBITORS OF ανβ6 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| WO-2020081154-A1 | INHIBITORS OF ανβ6 INTEGRIN | MORPHIC THERAPEUTIC, INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242524-A1 | INHIBITORS OF (ALPHA-V)(BETA-6) INTEGRIN | ITGB6, ITGA6, ITGAV | GPR119 1296/4885LMNA 2000/4885KMT2A 3926/4885 |
| US-12528803-B2 | Inhibitors of αvβ6 integrin | ITGB2, ITGB6, ITGA2 | GPR119 2859/4885LMNA 2231/4885KMT2A 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.